相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comment on Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
Haitang Yang et al.
BRITISH JOURNAL OF CANCER (2021)
CD73, Tumor Plasticity and Immune Evasion in Solid Cancers
Haitang Yang et al.
CANCERS (2021)
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The posttranslational modifications of Hippo-YAP pathway in cancer
Fangjie Yan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
TIGIT as an emerging immune checkpoint
H. Harjunpaa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Critical roles of phosphoinositides and NF2 in Hippo pathway regulation
Audrey W. Hong et al.
GENES & DEVELOPMENT (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC
Lingzhi Hong et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li et al.
NUCLEIC ACIDS RESEARCH (2020)
The regulation and function of CD20: an enigma of B-cell biology and targeted therapy
Gabriela Pavlasova et al.
HAEMATOLOGICA (2020)
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Runzhe Chen et al.
CLINICAL CANCER RESEARCH (2020)
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
Haitang Yang et al.
CANCERS (2020)
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
Duo Xu et al.
FRONTIERS IN ONCOLOGY (2020)
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer
Haitang Yang et al.
CANCERS (2020)
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
Haitang Yang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva et al.
LANCET ONCOLOGY (2019)
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy
Megan M. Tu et al.
SCIENCE ADVANCES (2019)
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Morihito Okada et al.
CLINICAL CANCER RESEARCH (2019)
Activation of Aurora A kinase increases YAP stability via blockage of autophagy
Peng Wang et al.
CELL DEATH & DISEASE (2019)
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Ping-Chih Hsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
Haitang Yang et al.
ONCOGENESIS (2019)
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
Duo Xu et al.
CANCERS (2019)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel et al.
LANCET ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2019)
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
Maria J. Disselhorst et al.
LANCET RESPIRATORY MEDICINE (2019)
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Hongxing Shen et al.
GENES & DISEASES (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
Helena J. Janse van Rensburg et al.
CANCER RESEARCH (2018)
Role of Hippo signaling in regulating immunity
Lixin Hong et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
Jeff DeFalco et al.
CLINICAL IMMUNOLOGY (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma
Tatsuhiro Sato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3
Vanesa Gregorc et al.
LANCET ONCOLOGY (2018)
Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia
Ana Paula Zambuzi Cardoso Marsola et al.
MEDICAL ONCOLOGY (2018)
YAP/TAZ upstream signals and downstream responses
Antonio Totaro et al.
NATURE CELL BIOLOGY (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Tissue-Specific Immunoregulation: A Call for Better Understanding of the Immunostat in the Context of Cancer
William Pao et al.
CANCER DISCOVERY (2018)
Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review
James J. Crawford et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Jutija Hmeljaki et al.
CANCER DISCOVERY (2018)
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Yumeng Wang et al.
CELL REPORTS (2018)
Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
Robin Tranchant et al.
CLINICAL CANCER RESEARCH (2017)
Targeting YAP in malignant pleural mesothelioma
Wen-Qian Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher A. Klebanoff et al.
JCI INSIGHT (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway
Ursula Ehmer et al.
MOLECULAR CANCER RESEARCH (2016)
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Matthew G. Rees et al.
NATURE CHEMICAL BIOLOGY (2016)
Role of Merlin/NF2 inactivation in tumor biology
A. M. Petrilli et al.
ONCOGENE (2016)
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Toshiro Moroishi et al.
CELL (2016)
NF2 Activates Hippo Signaling and Promotes Ischemia/Reperfusion Injury in the Heart
Takahisa Matsuda et al.
CIRCULATION RESEARCH (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics
Mingjing He et al.
CELL DIVISION (2016)
A critical role for NF2 and the Hippo pathway in branching morphogenesis
Antoine Reginensi et al.
NATURE COMMUNICATIONS (2016)
Hippo Pathway Gene Mutations in Malignant Mesothelioma Revealed by RNA and Targeted Exon Sequencing
Akihiko Miyanaga et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
Guangwu Guo et al.
CANCER RESEARCH (2015)
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
R. Mezzapelle et al.
BRITISH JOURNAL OF CANCER (2013)
Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators
Alfonso Lavado et al.
DEVELOPMENT (2013)
TCPA: a resource for cancer functional proteomics data
Jun Li et al.
NATURE METHODS (2013)
The Hippo pathway and human cancer
Kieran F. Harvey et al.
NATURE REVIEWS CANCER (2013)
Hippo-YAP and mTOR pathways collaborate to regulate organ size
Alfred Csibi et al.
NATURE CELL BIOLOGY (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity
M. Krusch et al.
CURRENT MEDICINAL CHEMISTRY (2011)
CD40-activated B cells contribute to mesothelioma tumor regression
Connie Jackaman et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation
Yoshitaka Sekido
PATHOLOGY INTERNATIONAL (2011)
Functional inactivation of NF2/merlin in human mesothelioma
Claudio Thurneysen et al.
LUNG CANCER (2009)
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas
D. Lallemand et al.
ONCOGENE (2009)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
Localization to the cortical cytoskeleton is necessary for Nf2/Merlin-dependent epidermal growth factor receptor silencing
Banumathi K. Cole et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17
C. Zhao et al.
ONCOGENE (2008)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study
Linda L. Garland et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Marcello Curto et al.
JOURNAL OF CELL BIOLOGY (2007)
ETS transcription factors and regulation of immunity
Sarah Gallant et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2006)
Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B
R Govindan et al.
CLINICAL CANCER RESEARCH (2005)
分享论文
